You are here

Prices & Quotes - UK Markets - Oxford Biomedica (OXB)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Down 909.00p
Change Today:
-47.00p
Market Cap:
783.33m
Sector:
Pharmaceuticals & Biotechnology

Novo Holdings pours ?53.5m into Oxford Biomedica

By Josh White

Date: Tuesday 28 May 2019

LONDON (ShareCast) - (Sharecast News) - Gene and cell therapy company Oxford Biomedica announced on Tuesday that Novo Holdings has agreed to invest up to 53.5m in the group, in return for new ordinary shares representing up to 10.1% of the outstanding shares after the capital increase.
The London-listed firm said the proceeds would be used to repay its existing debt facility with Oaktree Capital Management in full, and to further develop its 'LentiVector' platform and proprietary product portfolio.

It said the price per new ordinary share to be paid by Novo Holdings was equal to the closing market price on 24 May.

The Oxford Biomedica board said the company was "at the centre" of the "rapidly-emerging" gene and cell therapy sector, by which "life-changing and curative" treatment had become a therapeutic reality.

Leveraging its LentiVector platform, the firm said it benefitted from a dual strategy to support its partners in the development and commercialisation of their gene and cell therapy programmes, while also pursuing the development of a proprietary product portfolio for later out-licensing.

That strategy had resulted in a number of partnerships, including with Novartis and Sanofi, as well as the out-licensing of OXB-102 to Axovant Gene Therapies.

The investment from Novo Holdings would enable Oxford Biomedica to take advantage of its leading position, and further exploit the growth opportunities in the sector, the directors added.

"Novo Holdings is a well-known and highly regarded long-term investor with significant expertise in working with innovative, life sciences businesses to unlock their growth potential," said Oxford Biomedica chief executive officer John Dawson.

"This experience will be a great asset far beyond the financial commitment they have made to the group and their collaboration and support will be highly valuable as we seek to scale up our operations both on the platform and on the proprietary product portfolio."

Robert Ghenchev, director at Novo Holdings, added that Oxford Biomedica was a "global scientific and manufacturing leader" within lentiviral vectors, which he described as one of the most established and well-validated technologies for delivering gene and cell therapies.

"This investment underscores Novo Holdings' commitment to supporting companies developing cutting-edge science that makes a real difference to patients and society.

"We are genuinely excited about this investment and look forward to working with Oxford Biomedica and supporting the group going forward."

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OXB Market Data

Currency UK Pounds
Price 909.00p
Change Today -47.00p
52 Week High 1,634.00p
52 Week Low 905.00p
Volume 166,710
Shares Issued 86.18m
Market Cap 783.33m
Beta 0.03

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. full market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
Price Trend
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. empty sector
  4. empty sector
  5. empty sector
Income
Not Available
Growth
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. half sector star
  5. empty sector
Price Chg 6m
market
  1. half market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
P/E
Not Available
PEG
market
  1. full market star
  2. full market star
  3. full market star
  4. half market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. half sector star
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector

What The Brokers Say

Strong Buy 5
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 6
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for 21-Jan-2022

Time Volume / Share Price
16:37 15,000 @ 911.95p
16:35 30,499 @ 909.00p
16:29 91 @ 916.00p
16:29 8 @ 916.00p
16:29 8 @ 913.00p

OXB Key Personnel

CEO John Dawson
CFO Stuart Paynter